Head-To-Head Contrast: HCW Biologics (NASDAQ:HCWB) & Inhibrx Biosciences (NASDAQ:INBX)

HCW Biologics (NASDAQ:HCWB) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Insider & Institutional Ownership

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for HCW Biologics and Inhibrx Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1	0	1	0	2.00
Inhibrx Biosciences	1	2	2	1	2.50

HCW Biologics presently has a consensus target price of $30.00, suggesting a potential upside of 1,095.22%. Inhibrx Biosciences has a consensus target price of $197.50, suggesting a potential upside of 72.73%. Given HCW Biologics’ higher probable upside, equities analysts clearly believe HCW Biologics is more favorable than Inhibrx Biosciences.

Profitability

This table compares HCW Biologics and Inhibrx Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Volatility and Risk

HCW Biologics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.66, meaning that its share price is 266% more volatile than the S&P 500.

Valuation and Earnings

This table compares HCW Biologics and Inhibrx Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$6.72 million	0.69	-$7.96 million	($27.60)	-0.09
Inhibrx Biosciences	N/A	N/A	-$140.05 million	($8.88)	-12.88

HCW Biologics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

Inhibrx Biosciences beats HCW Biologics on 8 of the 14 factors compared between the two stocks.

About HCW Biologics

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.